Research Papers:

CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance

Stav Sapoznik, Sarit Aviel-Ronen, Keren Bahar-Shany, Oranit Zadok and Keren Levanon _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:62240-62247. https://doi.org/10.18632/oncotarget.19272

Metrics: PDF 1617 views  |   HTML 3750 views  |   ?  


Stav Sapoznik1,*, Sarit Aviel-Ronen2,3,4,*, Keren Bahar-Shany1, Oranit Zadok2 and Keren Levanon1,3,4

1Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan 52621, Israel

2Department of Pathology, Chaim Sheba Medical Center, Ramat-Gan 52621, Israel

3The Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Ramat Gan 52621, Israel

4Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv 69978, Israel

*These authors have contributed equally to this work

Correspondence to:

Keren Levanon, email: [email protected]

Keywords: CCNE1, ovarian cancer, predictive biomarker, chemoresistance, neoadjuvant chemotherapy

Received: February 22, 2017    Accepted: May 23, 2017    Published: July 15, 2017


Delayed diagnosis of ovarian cancer, as well as high recurrence rates and lack of personalized therapy options, are among the causes for poor survival figures. Much effort is made towards developing new therapeutic possibilities, however predictive biomarkers are still unavailable. CCNE1 amplification, occurring in ~20% of the high grade serous ovarian tumors, was previously proposed as a marker for platinum resistance and poor prognosis as well as for CDK2 inhibition. The current study aimed to examine the role of CCNE1 positive-immunostain as a predictor of first-line taxane-platinum chemoresistance. We evaluated matched pre- vs. post-neoadjuvant chemotherapy tumor samples and correlated the degree of pathological response to treatment with CCNE1 expression levels. Our results indicate that CCNE1 immunohistochemistry does not predict taxane-platinum chemoresistance in ovarian cancer patients. Further research is required in order to enable personalized adjuvant treatment, in cases where poor pathological response is achieved after the neoadjuvant phase.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19272